Is your company competent, interpersonal or community focused? The effect of values and brand portfolio on company reputation

Author:

Katsanis Lea Prevel,Williams Alan,Srirangan Kajan

Abstract

Purpose The purpose of this study is twofold: first, to determine if pharmaceutical companies can be grouped based on their espoused values, and second, to examine the relationship between these values and company reputation. Design/methodology/approach A descriptive study design is used with two separate analyses: cluster analysis for grouping the companies; and descriptive data analysis for determining cluster differences. Findings The findings suggest that there are three value clusters: competent, community and interpersonal, with the community group showing the highest relative reputation, and the interpersonal cluster as the lowest. Brand portfolio composition appears to positively contribute to reputation. The effect of portfolio specialization is based on a company’s closeness to its therapeutic community, which may be influenced by the outward characteristics of its values. Research limitations/implications Future research should examine the longitudinal effects of values on reputation combined with case studies. Practical implications Regardless of cluster classification, all firms should develop strong ties with their therapeutic communities using both personal and digital/omnichannel strategies. Social implications A company’s values are becoming an important consideration for all customers and stakeholders. Originality/value To the best of the authors’ knowledge, this study is the first to systematically examine the activities of leading pharmaceutical firms to link a specific value cluster to company reputation.

Publisher

Emerald

Subject

Marketing,Health Policy

Reference63 articles.

1. Pharma brands make the biggest splash for TV ad debuts so far this year,2023

2. Blankenship, K. (2020), “Gilead asks FDA to rescind remdesivir orphan drug tag after public backlash”, FiercePharma, 25 March, available at: www.fiercepharma.com/pharma/gilead-asks-fda-to-rescind-remdesivir-orphan-drug-tag-after-public-backlash

3. Bleys, J., Coravos, J., Fleming, E. and Quigley, D. (2021), “A new portfolio model for biotech”, available at: www.mckinsey.com/industries/life-sciences/our-insights/a-new-portfolio=model-for-biotech

4. Organizational values: a dynamic perspective;Organization Studies,2013

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Public perception management;Strategic Direction;2024-01-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3